Pain Control with Morphine for Vertebral Metastases and Sciatica in Advanced Cancer Patients

1994 ◽  
Vol 10 (1) ◽  
pp. 10-13 ◽  
Author(s):  
Hideo Yoshioka ◽  
Satoru Tsuneto ◽  
Tetsuo Kashiwagi
Keyword(s):  
Bone Metastases ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Bone Pain ◽  
Malignant Tumors ◽  
Spinal Metastases ◽  
Pelvic Bone ◽  
Advanced Cancer Patients ◽  
Direct Invasion ◽  
High Doses

Morphine was administered to 56 advanced cancer patients; of that number spinal metastases had induced bone pain in 28 and malignant tumors had induced sciatica in 28. The sciatica was caused in 16 patients by direct invasion of the sacral plexus, in four by lumbar bone metastases, and in eight by pelvic bone metastases. Spinal bone pain was controlled adequately with morphine. However, sciatica required larger dosages of morphine than did bone pain. Among the group with sciatica, rectal cancer patients needed larger dosages of morphine than the other cancer patients. Even with high doses of morphine, it was occasionally difficult to control neuropathic pain of the sciatic nerve caused by intrapelvic cancer.

Pharmacokinetics of repeated i.v. bolus administration of high doses of r-met-Hu interleukin-2 in advanced cancer patients

1990 ◽  
Vol 26 (5) ◽  
pp. 355-358 ◽  
Author(s):  
J. P. Sculier ◽  
J. J. Body ◽  
N. Donnadieu ◽  
S. Nejai ◽  
F. Glibert ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Advanced Cancer ◽  
Interleukin 2 ◽  
Bolus Administration ◽  
Advanced Cancer Patients ◽  
High Doses

scholarly journals Pre-treatment expectations of patients with spinal metastases: what do we know and what can we learn from other disciplines? A systematic review of qualitative studies

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
R. Gal ◽  
D. Oostinga ◽  
H. Wessels ◽  
J. J. Verlaan ◽  
R. Charest-Morin ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Cancer Care ◽  
Spinal Surgery ◽  
Symptom Relief ◽  
Spinal Metastases ◽  
Advanced Cancer Patients ◽  
Treatment Expectations ◽  
Pre Treatment

Abstract Background Little is known about treatment expectations of patients with spinal metastases undergoing radiotherapy and/or surgery. Assuming that patients with spinal metastases share characteristics with patients who had spinal surgery for non-cancer related conditions and with advanced cancer patients, we performed a systematic review to summarize the literature on patient expectations regarding treatment outcomes of spinal surgery and advanced cancer care. Methods A comprehensive search was performed in MEDLINE, EMBASE and PsycINFO for studies between 2000 and sep-2019. Studies including adult patients (> 18 years), undergoing spinal surgery or receiving advanced cancer care, investigating patients’ pre-treatment expectations regarding treatment outcomes were included. Two independent reviewers screened titles, abstracts and full-texts, extracted data and assessed methodological quality. Results The search identified 7343 articles, of which 92 were selected for full-text review. For this review, 31 articles were included. Patients undergoing spinal surgery had overly optimistic expectations regarding pain and symptom relief, they underestimated the probability of functional disability, and overestimated the probability of (complete) recovery and return to work. Studies highlighted that patients feel not adequately prepared for surgery in terms of post-treatment expectations. Similarly, advanced cancer patients receiving palliative treatment often had overly optimistic expectations regarding their survival probability and cure rates. Conclusions Patients tend to have overly optimistic expectations regarding pain and symptom relief, recovery and prognosis following spinal surgery or advanced cancer care. Pretreatment consultation about the expected pain and symptom relief, recovery and prognosis may improve understanding of prognosis, and promote and manage expectations, which, in turn, may lead to better perceived outcomes. Trial registration PROSPERO registration number: CRD42020145151.

scholarly journals Antitumor Effects of Selenium

2021 ◽  
Vol 22 (21) ◽  
pp. 11844
Author(s):  
Seung Jo Kim ◽  
Min Chul Choi ◽  
Jong Min Park ◽  
An Sik Chung
Keyword(s):  
Radiation Therapy ◽  
Cancer Cells ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Sodium Selenite ◽  
Subsequent Treatment ◽  
Advanced Cancer Patients ◽  
Antitumor Effects ◽  
Hydrogen Selenide ◽  
High Doses

Functions of selenium are diverse as antioxidant, anti-inflammation, increased immunity, reduced cancer incidence, blocking tumor invasion and metastasis, and further clinical application as treatment with radiation and chemotherapy. These functions of selenium are mostly related to oxidation and reduction mechanisms of selenium metabolites. Hydrogen selenide from selenite, and methylselenol (MSeH) from Se-methylselenocyteine (MSeC) and methylseleninicacid (MSeA) are the most reactive metabolites produced reactive oxygen species (ROS); furthermore, these metabolites may involve in oxidizing sulfhydryl groups, including glutathione. Selenite also reacted with glutathione and produces hydrogen selenide via selenodiglutathione (SeDG), which induces cytotoxicity as cell apoptosis, ROS production, DNA damage, and adenosine-methionine methylation in the cellular nucleus. However, a more pronounced effect was shown in the subsequent treatment of sodium selenite with chemotherapy and radiation therapy. High doses of sodium selenite were effective to increase radiation therapy and chemotherapy, and further to reduce radiation side effects and drug resistance. In our study, advanced cancer patients can tolerate until 5000 μg of sodium selenite in combination with radiation and chemotherapy since the half-life of sodium selenite may be relatively short, and, further, selenium may accumulates more in cancer cells than that of normal cells, which may be toxic to the cancer cells. Further clinical studies of high amount sodium selenite are required to treat advanced cancer patients.

The effects of denosumab on calcium profiles in advanced cancer patients with bone metastases

2014 ◽  
Vol 22 (7) ◽  
pp. 1765-1771 ◽  
Author(s):  
Breanne Lechner ◽  
Carlo DeAngelis ◽  
Noreen Jamal ◽  
Urban Emmenegger ◽  
Natalie Pulenzas ◽  
...  
Keyword(s):  
Bone Metastases ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Advanced Cancer Patients

scholarly journals Determinants of quality of life in advanced cancer patients with bone metastases undergoing palliative radiation treatment

2013 ◽  
Vol 21 (11) ◽  
pp. 3021-3030 ◽  
Author(s):  
Kinsey Lam ◽  
Edward Chow ◽  
Liying Zhang ◽  
Erin Wong ◽  
Gillian Bedard ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Radiation Treatment ◽  
Advanced Cancer Patients ◽  
Palliative Radiation

A palliative radiation oncology consult service’s impact on care of advanced cancer patients with symptomatic bone metastases.

2015 ◽  
Vol 33 (29_suppl) ◽  
pp. 110-110
Author(s):  
Sanders Chang ◽  
Cardinale B. Smith ◽  
R. Sean Morrison ◽  
Kenneth Rosenzweig ◽  
Kavita Vyas Dharmarajan
Keyword(s):  
Palliative Care ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Radiation Oncology ◽  
Cancer Type ◽  
Advanced Cancer Patients ◽  
Palliative Radiation ◽  
The Impact ◽  
Pain Improvement

110 Background: Single-fraction and ≤ 5 fraction radiation treatment (SF-RT and Hypo-RT, respectively) is underutilized despite strong evidence regarding its efficacy in symptom management. Established in 2013, the Palliative Radiation Oncology Consult Service (PROC) is a specialty service designed to provide individualized, efficient treatment for advanced cancer patients by a radiation oncology team with a dedicated palliative care focus. We assessed the impact of this new model of care on use of SF-RT, hypo-RT, pain improvement, palliative care utilization, and hospitalization among patients treated with palliative radiation (PRT) for painful bone metastases. Methods: We searched electronic charts of advanced cancer patients who had PRT for symptomatic bone mets from Dec 2010 to April 2015, extracting PRT details, demographics, cancer type, pain pre- and 1 month post-PRT, comorbidities (summarized using Charlson comorbidity index [CCI]), palliative care consults, and hospitalization. Comparisons were made before and after PROC using chi-square or t-tests. Multivariable logistic regression estimated the likelihood of SF-RT or hypo-RT, controlling for age, gender, cancer type, treatment site, and CCI. Results: We identified 334 patients, described in the table below. Patients were more likely to have SF-RT (OR 2.2, 95% CI [1.2-3.8], p = 0.007), or hypo-RT (OR 3.0, 95% CI [1.8-4.7], p < 0.001) after establishment of PROC. Conclusions: Establishment of a PROC service nearly doubled utilization of SF-RT and hypo-RT while maintaining pain improvement, and was associated with an increased use of palliative care consult services, decreased inpatient PRT use, and decreased length of stay. A dedicated service combining palliative care principles and radiation oncology improved quality of palliative cancer care. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document